Date: 2017-08-01
Type of information: Licensing agreement
Compound: monoclonal antibody
Company: Takeda Pharmaceutical (Japan) Isogenica (UK)
Therapeutic area:
Type agreement: licensing
Action mechanism:
Disease:
Details:
- • On August 1, 2017, Isogenica announced a new licensing deal with Takeda Pharmaceutical. Under the terms of the agreement, Isogenica has granted Takeda licences to its family of llamdA™ VHH single-domain antibody libraries for the discovery, development and commercialisation of therapeutic products derived from these libraries.
Financial terms:
- Isogenica is entitled to an upfront and annual licence payments. If antibodies are advanced into development, Isogenica is entitled to further licence fees, milestones and royalties.
Latest news:
Is general: Yes
